# MTO1

## Overview
The MTO1 gene encodes the mitochondrial tRNA translation optimization 1 protein, which plays a pivotal role in mitochondrial function by facilitating the posttranscriptional modification of mitochondrial tRNAs. This protein is categorized as a tRNA modification enzyme and is essential for the 5-carboxymethylaminomethylation of the wobble uridine base in specific mitochondrial tRNAs, a modification crucial for the accuracy and efficiency of mitochondrial DNA translation (Ghezzi2012Mutations; Baruffini2013MTO1). The MTO1 protein shares structural similarities with its eubacterial ortholog, GidA, and is involved in maintaining the fidelity of mitochondrial protein synthesis, which is vital for the proper assembly and function of oxidative phosphorylation complexes (Tischner2014MTO1; Baruffini2013MTO1). Mutations in the MTO1 gene are linked to various mitochondrial disorders, including hypertrophic cardiomyopathy and lactic acidosis, highlighting its clinical significance (Ghezzi2012Mutations; Baruffini2013MTO1).

## Structure
The human MTO1 protein shares structural similarities with its eubacterial ortholog, GidA, which has been resolved in several bacteria. GidA contains four domains: an α/β FAD-binding domain, a small N-terminal insertion-domain 1, a large α/β insertion-domain 2 that binds NADH, and a large α C-terminal domain that contributes to tRNA binding and dimerization with MnmE. The human MTO1 protein shares conserved motifs with GidA, particularly in the FAD-binding domain (Baruffini2013MTO1).

The MTO1 protein is involved in the posttranscriptional modification of mitochondrial tRNAs, specifically catalyzing the 5-carboxymethylaminomethylation of the wobble uridine base in specific mitochondrial tRNAs. This function is crucial for the accuracy and efficiency of mitochondrial DNA translation (Baruffini2013MTO1). Mutations in MTO1, such as Thr411Ile and Arg477His, affect the protein's ability to bind FAD and tRNA, respectively, due to alterations in conserved motifs and loops that are critical for these interactions (Baruffini2013MTO1).

The MTO1 protein's structure is essential for its role in mitochondrial function, and mutations can lead to defects in mitochondrial respiratory chain activities, as evidenced by studies using yeast models (Baruffini2013MTO1).

## Function
The MTO1 gene encodes a protein that plays a critical role in mitochondrial function by modifying mitochondrial tRNA, which is essential for accurate and efficient mitochondrial protein synthesis. This modification involves the 5-carboxymethylaminomethylation of the wobble uridine base in mitochondrial tRNAs, specifically those for glutamine, glutamic acid, and lysine, among others (Ghezzi2012Mutations; Baruffini2013MTO1). These modifications are crucial for maintaining the accuracy and efficiency of mitochondrial DNA translation, which is vital for the proper assembly and function of oxidative phosphorylation (OXPHOS) complexes (Boutoual2018Defects; Tischner2014MTO1).

In healthy human cells, MTO1 ensures the correct translation of mitochondrial DNA, supporting the oxidative phosphorylation process, which is the primary energy supply pathway for cells, particularly in energy-demanding tissues like the heart (Ghezzi2012Mutations). MTO1 interacts with mitoribosomal proteins, aiding in the assembly or stability of the mitochondrial ribosome, which is essential for maintaining translation fidelity and efficiency (Tischner2014MTO1). The gene's function is linked to nutrient sensing, suggesting that MTO1 is part of a nutrient-sensing program within mitochondria, linking translation fidelity to nutrient supply (Tischner2014MTO1).

## Clinical Significance
Mutations in the MTO1 gene are associated with several mitochondrial disorders, primarily hypertrophic cardiomyopathy and lactic acidosis. These conditions arise due to impaired mitochondrial function, which affects the energy production in cells. MTO1 is crucial for the posttranscriptional modification of mitochondrial tRNAs, specifically the 5-carboxymethylaminomethylation of the wobble uridine base, which is essential for accurate mitochondrial protein synthesis (Ghezzi2012Mutations).

Patients with MTO1 mutations often present with hypertrophic cardiomyopathy, a condition characterized by the thickening of the heart muscle, and lactic acidosis, which results from the accumulation of lactate due to defective oxidative phosphorylation (Ghezzi2012Mutations; Baruffini2013MTO1). These mutations can lead to multiple defects in mitochondrial respiratory chain activities, further exacerbating the clinical manifestations (Baruffini2013MTO1).

In addition to cardiomyopathy and lactic acidosis, MTO1 mutations have been linked to optic neuropathy, developmental delays, and cognitive disabilities. The phenotypic expression of these mutations can vary significantly, with some patients experiencing severe symptoms and others having milder forms of the disease (Charif2015Optic; Li2019Novel). The variability in clinical presentation underscores the complexity of MTO1-related disorders and the importance of genetic analysis for accurate diagnosis (O’Byrne2018The).

## Interactions
The MTO1 protein is involved in the post-transcriptional modification of mitochondrial tRNAs, working in conjunction with MSS1 and MTO2. This complex catalyzes the biosynthesis of 5-carboxymethylaminomethylation of the wobble uridine base in mt-tRNA Gln, mt-tRNA Glu, and mt-tRNA Lys, which is crucial for the accuracy and efficiency of mtDNA translation (Zhu2015MTO1). MTO1 and MSS1 are responsible for the C5 substituent of the modified uridine, while MTO2 is responsible for the 2-thiolation of the U34 nucleotide (Zhu2015MTO1).

MTO1 interacts with mitochondrial 15S rRNA, and this interaction is crucial for maintaining mitochondrial function. The C1477G mutation in 15S rRNA affects mitochondrial function and sensitivity to neomycin, highlighting the importance of MTO1 in these processes (Zhu2015MTO1). The deletion of MTO1 can regulate neomycin sensitivity in yeast carrying the mitochondrial 15S rRNA C1477G mutation, potentially through the up-regulation of glycolytic genes to compensate for impaired mitochondrial function (Zhu2015MTO1).

These interactions underscore the role of MTO1 in mitochondrial tRNA modification and its broader impact on mitochondrial function and antibiotic sensitivity.


## References


[1. (Li2019Novel) Emily Li, Valentina Emmanuele, Francine Testa, Cristiane De Araujo Martins Moreno, Michio Hirano, and Robert L. Lesser. Novel mitochondrial translation optimizer-1 mutations as a cause of hereditary optic neuropathy. Journal of Neuro-Ophthalmology, 40(3):406–410, December 2019. URL: http://dx.doi.org/10.1097/wno.0000000000000858, doi:10.1097/wno.0000000000000858. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/wno.0000000000000858)

[2. (Baruffini2013MTO1) Enrico Baruffini, Cristina Dallabona, Federica Invernizzi, John W. Yarham, Laura Melchionda, Emma L. Blakely, Eleonora Lamantea, Claudia Donnini, Saikat Santra, Suresh Vijayaraghavan, Helen P. Roper, Alberto Burlina, Robert Kopajtich, Anett Walther, Tim M. Strom, Tobias B. Haack, Holger Prokisch, Robert W. Taylor, Ileana Ferrero, Massimo Zeviani, and Daniele Ghezzi. Mto1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast. Human Mutation, 34(11):1501–1509, September 2013. URL: http://dx.doi.org/10.1002/humu.22393, doi:10.1002/humu.22393. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22393)

[3. (Ghezzi2012Mutations) Daniele Ghezzi, Enrico Baruffini, Tobias B. Haack, Federica Invernizzi, Laura Melchionda, Cristina Dallabona, Tim M. Strom, Rossella Parini, Alberto B. Burlina, Thomas Meitinger, Holger Prokisch, Ileana Ferrero, and Massimo Zeviani. Mutations of the mitochondrial-trna modifier mto1 cause hypertrophic cardiomyopathy and lactic acidosis. The American Journal of Human Genetics, 90(6):1079–1087, June 2012. URL: http://dx.doi.org/10.1016/j.ajhg.2012.04.011, doi:10.1016/j.ajhg.2012.04.011. This article has 161 citations.](https://doi.org/10.1016/j.ajhg.2012.04.011)

[4. (Charif2015Optic) Majida Charif, Salah Mohamed Cherif Titah, Agathe Roubertie, Valérie Desquiret‐Dumas, Naig Gueguen, Isabelle Meunier, Jean Leid, Frédéric Massal, Xavier Zanlonghi, Jacques Mercier, Eric Raynaud de Mauverger, Vincent Procaccio, Bénédicte Mousson de Camaret, Guy Lenaers, and Christian P. Hamel. Optic neuropathy, cardiomyopathy, cognitive disability in patients with a homozygous mutation in the nuclear mto1 and a mitochondrial mt‐tf variant. American Journal of Medical Genetics Part A, 167(10):2366–2374, June 2015. URL: http://dx.doi.org/10.1002/ajmg.a.37188, doi:10.1002/ajmg.a.37188. This article has 23 citations.](https://doi.org/10.1002/ajmg.a.37188)

[5. (Tischner2014MTO1) Christin Tischner, Annette Hofer, Veronika Wulff, Joanna Stepek, Iulia Dumitru, Lore Becker, Tobias Haack, Laura Kremer, Alexandre N. Datta, Wolfgang Sperl, Thomas Floss, Wolfgang Wurst, Zofia Chrzanowska-Lightowlers, Martin Hrabe De Angelis, Thomas Klopstock, Holger Prokisch, and Tina Wenz. Mto1 mediates tissue specificity of oxphos defects via trna modification and translation optimization, which can be bypassed by dietary intervention. Human Molecular Genetics, 24(8):2247–2266, December 2014. URL: http://dx.doi.org/10.1093/hmg/ddu743, doi:10.1093/hmg/ddu743. This article has 43 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddu743)

[6. (Zhu2015MTO1) Xiaoyu Zhu, Xiangyu He, Wei Wang, Qiyin Zhou, Zhe Yu, Yu Dai, Xufen Zhu, and Qingfeng Yan. Mto1 worked as a modifier in the aminoglycosides sensitivity of yeast carrying a mitochondrial 15s rrna c1477g mutation. PLOS ONE, 10(4):e0124200, April 2015. URL: http://dx.doi.org/10.1371/journal.pone.0124200, doi:10.1371/journal.pone.0124200. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0124200)

[7. (Boutoual2018Defects) Rachid Boutoual, Salvador Meseguer, Magda Villarroya, Elena Martín-Hernández, Mohammed Errami, Miguel A. Martín, Marta Casado, and M.-Eugenia Armengod. Defects in the mitochondrial-trna modification enzymes mto1 and gtpbp3 promote different metabolic reprogramming through a hif-pparγ-ucp2-ampk axis. Scientific Reports, January 2018. URL: http://dx.doi.org/10.1038/s41598-018-19587-5, doi:10.1038/s41598-018-19587-5. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-018-19587-5)

[8. (O’Byrne2018The) James J. O’Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123(1):28–42, January 2018. URL: http://dx.doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2017.11.003)